Decipher Urologic Cancers, a part of Veracyte, Inc., is focused on genomic testing to help treatment planning for urologic cancers. Decipher's prostate cancer genomic testing provides meaningful and independent data to assess the underlying biology and risk of an individual patient’s disease. The test has been validated in 42 studies of more than 30,000 patients as the most accurate predictor of metastasis, prostate cancer-specific mortality, and overall survival.
Developed from a large cohort of post-prostatectomy prostate cancer patients treated at the Mayo Clinic, with long-term follow-up, the whole-transcriptome test utilizes 22 coding and non-coding biomarkers that span seven cancer pathways to provide a more accurate, independent prediction of risk.
When used in conjunction with clinical information, Decipher provides clarity and confidence in treatment planning.